Tech Millionaire Sets Record Straight on $56 Trillion Opportunity
The man who recommended Microsoft when it was trading for pennies steps forward to reveal the number one secret that absolutely no one is talking about… According to him, it could worth $56 trillion…
Get the full story here.
Timothy P. Walbert, insider at Horizon Therapeutics Public
Timothy P. Walbert Insider Alerts

Get notified the next time Timothy P. Walbert buys or sells Horizon Therapeutics Public stock. Enter your email address below to get our daily insider buying and selling report.

Timothy P. Walbert Insider Information

Tim Walbert joined Horizon in June 2008 as president and chief executive officer and has served as chairman of the company’s board of directors since 2010. Before joining Horizon, he served as president, chief executive officer and director of IDM Pharma Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings Inc., or Takeda, in June 2009. Before IDM, Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional vice president, global cardiovascular strategy. From 1998 to 2001, Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America and Canada, at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co. Inc. and Wyeth.

Walbert received his Bachelor of Arts in business from Muhlenberg College in Allentown, Pa. He serves as chairman of the board of Exicure Inc. and serves on the board of Aurinia Pharmaceuticals Inc. and the Illinois Biotechnology Innovation Organization (iBIO). He is a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served on the boards of directors of Raptor Pharmaceutical Corp., a public biopharmaceutical company, from 2010 to 2014; XOMA Corporation, a public biotechnology company, from 2011 to 2017; and Sucampo Pharmaceuticals Inc., a public biopharmaceutical company, from 2016 to 2018.

What is Timothy P. Walbert's net worth?

The estimated net worth of Timothy P. Walbert is at least $81.06 million as of April 30th, 2021. Mr. Walbert owns 920,710 shares of Horizon Therapeutics Public stock worth more than $81,059,308 as of January 20th. This net worth evaluation does not reflect any other assets that Mr. Walbert may own. Learn More.

What is Timothy P. Walbert's salary?

As the CEO of Horizon Therapeutics Public Limited, Mr. Walbert earned a total compensation package of $21,632,803.00 in 2020. Mr. Walbert earned a salary of $1,146,542.00, stock awards of $16,149,668.00, non-equity compensation of $4,137,046.00, and other compensation of $199,548.00.

How do I contact Timothy P. Walbert?

The corporate mailing address for Mr. Walbert and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]

Has Timothy P. Walbert been buying or selling shares of Horizon Therapeutics Public?

In the last ninety days, Timothy P. Walbert has sold $2,250,500.00 of Horizon Therapeutics Public stock. Most recently, Timothy P. Walbert sold 25,000 shares of the business's stock in a transaction on Friday, January 14th. The shares were sold at an average price of $90.02, for a transaction totalling $2,250,500.00.

Who are Horizon Therapeutics Public's active insiders?

Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Geoffrey Curtis (EVP), William Daniel (Director), Michael Grey (Director), Paul Hoelscher (CFO), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO).

Are insiders buying or selling shares of Horizon Therapeutics Public?

During the last twelve months, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 735,485 shares worth more than $71,889,056.61. The most recent insider tranaction occured on January, 14th when CEO Timothy P Walbert sold 25,000 shares worth more than $2,250,500.00. Insiders at Horizon Therapeutics Public own 3.2 % of the company.

Information on this page was last updated on 1/14/2022.

Timothy P. Walbert Insider Trading History at Horizon Therapeutics Public

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/14/2022Sell25,000$90.02$2,250,500.00View SEC Filing Icon  
11/30/2021Sell50,000$102.40$5,120,000.00View SEC Filing Icon  
11/1/2021Sell25,000$118.49$2,962,250.00View SEC Filing Icon  
9/30/2021Sell50,000$110.30$5,515,000.00View SEC Filing Icon  
7/30/2021Sell25,000$101.74$2,543,500.00View SEC Filing Icon  
4/30/2021Sell25,000$94.98$2,374,500.00920,710View SEC Filing Icon  
1/22/2021Sell11,323$76.47$865,869.81966,889View SEC Filing Icon  
1/15/2021Sell211,204$77.89$16,450,679.561,076,362View SEC Filing Icon  
2/21/2020Sell93,864$35.23$3,306,828.72963,064View SEC Filing Icon  
1/6/2020Sell84,886$35.57$3,019,395.02987,991View SEC Filing Icon  
10/15/2019Sell320,174$28.02$8,971,275.48892,483View SEC Filing Icon  
8/30/2019Sell2,500$28.00$70,000.00785,296View SEC Filing Icon  
11/14/2018Sell408,347$21.54$8,795,794.38650,404View SEC Filing Icon  
6/1/2018Sell83,353$16.17$1,347,818.01View SEC Filing Icon  
11/19/2014Sell150,000$12.05$1,807,500.00View SEC Filing Icon  
See Full Table

Timothy P. Walbert Buying and Selling Activity at Horizon Therapeutics Public

This chart shows Timothy P Walbert's buying and selling at Horizon Therapeutics Public by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public logo
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $88.04
Low: $87.31
High: $90.78

50 Day Range

MA: $102.86
Low: $88.04
High: $109.87

2 Week Range

Now: $88.04
Low: $70.15
High: $120.54

Volume

1,529,382 shs

Average Volume

1,667,943 shs

Market Capitalization

$19.97 billion

P/E Ratio

37.95

Dividend Yield

N/A

Beta

1.03
5 Free Wealth Stock Picks
5 free stock picks that could set you up for a fresh new start in 2022.
Learn More.